Delivery Order SPE2DB22D2206-SPE2DB25FKA22
- Not listed
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ocrevus 300 mg/10 ml vials. The contract, valued at $120,192.80 with a firm fixed price structure, represents a competitively awarded, non-set-aside delivery order with an ultimate completion date of October 8, 2025. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $12,019.28 delivery order to AmerisourceBergen Drug Corp on August 21, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 12, 2025, and performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $120,192.80 and firm fixed pricing. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This is an unrestricted, competitively awarded delivery order with no set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ocrevus 300 mg/10 mL vials valued at $32,694.46 under a firm fixed-price contract. The delivery order is non-set-aside and competitively awarded, with a completion date of June 24, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ocrevus 300 mg/10 ml vials with a ceiling value of $36,057.84 under a firm fixed-price contract structure. The order is set to be completed by September 10, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation, reflecting open competition among...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Ocrevus 300 mg/10 mL vials, valued at $96,154.24 with a firm fixed price structure. The award is non-competitive with no set-aside designation and is scheduled for completion by October 2, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which...
- The Defense Logistics Agency awarded a delivery order valued at $72,115.74 to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This competitively awarded, firm fixed-price contract is scheduled for completion by October 20, 2025, with performance occurring at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $24,038.58 to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Ocrevus 300 mg/10 mL vials. This is a firm fixed price delivery order with an ultimate completion date of June 24, 2025, and represents a non-competitive, non-set-aside award. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a contract ceiling value of $43,178.96 under firm fixed price terms. This non-set-aside, competitively awarded delivery order is scheduled for completion by September 16, 2025, with performance taking place at AmerisourceBergen's facility in Conshohocken, Pennsylvania. Ocrevus is a specialty pharmaceutical product used in the treatment of...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Ocrevus 300 mg/10 mL vials valued at $48,077.16. This is a firm fixed-price delivery order with an ultimate completion date of October 9, 2025, and represents a non-competitive award under the company's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate office location in...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FKA22Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Ocrevus 300 mg/10 mL vials with a ceiling value of $120,192.80 and a firm fixed price structure. The order is scheduled for completion by October 14, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This non-competitive delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, a $999,999,999.00 prime vendor agreement valued through December 2026 that authorizes the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, has established itself as a critical federal medical procurement vendor through consistent competitively awarded contracts with the Defense Logistics Agency. The company's federal contract portfolio demonstrates extensive expertise in delivering specialty medications, vaccines, and medical supplies across multiple therapeutic domains to support Defense Health Agency and U.S. military healthcare systems. This delivery order for Ocrevus, a specialty pharmaceutical used in treating neurological conditions, exemplifies the contractor's role in ensuring the availability of essential branded medications throughout the military medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $120.2k | 9/22/25 |